Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plozasiran - Arrowhead Pharmaceuticals

Next Previous
Drug Profile

Plozasiran - Arrowhead Pharmaceuticals

Alternative Names: ARO-APOC3; REDEMPLO; VSA-001

Latest Information Update: 05 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
  • Mechanism of Action Apolipoprotein C-III expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hyperlipoproteinaemia type I
  • Phase III Hyperlipidaemia; Hypertriglyceridaemia
  • Phase II Dyslipidaemias

Most Recent Events

  • 03 Dec 2025 Plozasiran - Arrowhead Pharmaceuticals receives Breakthrough Therapy status for Hypertriglyceridaemia in USA
  • 02 Dec 2025 Arrowhead Pharmaceuticals announces intention to submit sNDA to US FDA for Hypertriglyceridaemia by end of 2026
  • 18 Nov 2025 Registered for Hyperlipoproteinaemia type I (Treatment-experienced) in USA (SC) - First global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top